By Associate Professor Hao-Wen Sim

Journal articles

Sim HW; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX, 2019, 'Tissue 2-hydroxyglutarate as a biomarker for isocitrate dehydrogenase mutations in gliomas', Clinical Cancer Research, 25, pp. 3366 - 3373, http://dx.doi.org/10.1158/1078-0432.CCR-18-3205

Ma LX; Espin-Garcia O; Lim CH; Sun P; Jiang DM; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Suzuki C; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2019, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4069

Herman M; Zhang Y; Wang L; Sim H-W; Knox JJ, 2019, 'Impact of HCV treatment in patients with advanced hepatocellular carcinoma on sorafenib.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.e15645

Jiang DM; Suzuki C; Espin-Garcia O; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW-J; Elimova E, 2019, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.e15579

Kroeger N; Li H; De Velasco G; Donskov F; Sim H-W; Stuehler V; Wells JC; Stukalin I; Heide J; Bedke J; Agarwal N; Parekh H; Rini B; Knox EJ; Pantuck A; Choueiri TK; Heng DYC, 2019, 'Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies', CLINICAL GENITOURINARY CANCER, 17, pp. 65 - 71, http://dx.doi.org/10.1016/j.clgc.2018.09.006

Ma LX; Espin-Garcia O; Lim CH; Sun P; Jiang DM; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Suzuki C; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2019, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.164

Taylor K; Espin-Garcia O; Jiang DM; Yokom D; Ma LX; Lim CH; Chan BA; Sun P; Sim H-W; Natori A; Liu G; Darling GE; Wong R; Chen EX; Jang RW-J; Veit-Haibach P; Rozenberg D; Elimova E, 2019, 'Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.171

Fung AS; Tam VC; Meyers DE; Sim H-W; Knox JJ; Zaborska VO; Davies JM; Ko Y-J; Batuyong E; Cheung WY; Samawi H; Lee-Ying RM, 2019, 'Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.422

Jiang DM; Suzuki C; Espin-Garcia O; Pintilie M; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW-J; Elimova E, 2019, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.162

Fung AS; Lee-Ying RM; Meyers DE; Sim H-W; Knox JJ; Zaborska VO; Davies JM; Ko Y-J; Batuyong E; Cheung WY; Samawi H; Tam VC, 2019, 'Treatment of hepatocellular carcinoma (HCC) after sorafenib (S) over the last 10 years.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.438

Natori A; Chan BA; Sim HW; Ma L; Yokom DW; Chen E; Liu G; Darling G; Swallow C; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox J; Elimova E; Jang RW, 2018, 'Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer', Current Oncology, 25, pp. 366 - 370, http://dx.doi.org/10.3747/co.25.4208

Nejad R; Nassiri F; Mamatjan Y; Sim H-W; Chen E; Agnihotri S; Aldape K; Zadeh G, 2018, 'CBMT-06. LOWER GRADE ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS METABOLICALLY MIMICKING GLIOBLASTOMA (GBM) EXPRESS HIGHER R:S 2-HYDROXYGLUTARATE RATIOS RELATIVE TO NON-GBM-MIMICKING IDH MUTANT GLIOMAS', Neuro-Oncology, 20, pp. vi33 - vi33, http://dx.doi.org/10.1093/neuonc/noy148.125

Mitchell L; Tam S; Lewin J; Srikanthan A; Heck C; Hodgson D; Vakeesan B; Sim HW; Gupta A, 2018, 'Measuring the impact of an adolescent and young adult program on addressing patient care needs', Journal of Adolescent and Young Adult Oncology, 7, pp. 612 - 617, http://dx.doi.org/10.1089/jayao.2018.0015

Sim H-W; Stundzia A; Pierre S; Metser U; O'Malley M; Elimova E; Sridhar SS; Hansen A, 2018, 'Predictive radiomics signature for treatment response to nivolumab in patients (pts) with advanced renal cell carcinoma (RCC)', ANNALS OF ONCOLOGY, 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277302079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Meyers DE; Lee-Ying R; Alghamdi M; Sim H-W; Zaborska VO; Ko Y-J; Raycraft T; Batuyong E; Cheung WY; Samawi H; Davies JM; Tam VC, 2018, 'Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database', ANNALS OF ONCOLOGY, 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277301285&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2018, 'Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium', Cancer, 124, pp. 3677 - 3683, http://dx.doi.org/10.1002/cncr.31595

Samawi HH; Sim HW; Chan KK; Alghamdi MA; Lee-Ying RM; Knox JJ; Gill P; Romagnino A; Batuyong E; Ko YJ; Davies JM; Lim HJ; Cheung WY; Tam VC, 2018, 'Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database', Cancer Medicine, 7, pp. 2816 - 2825, http://dx.doi.org/10.1002/cam4.1493

Natori A; Sim H-W; Chan BA; Sun P; Moignard S; Yokom D; Lim CH; Jiang DM; Ma LX; Chen EX; Liu G; Knox JJ; Darling GE; Yeung JC-W; Wong R; Hafezi-Bakhtiari S; Conner J; Rogalla P; Jang RW-J; Elimova E, 2018, 'Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 36, pp. 4066 - 4066, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.4066

Lim CH; Yokom D; Jiang DM; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Moignard S; Knox JJ; Chen EX; Liu G; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Outcomes for advanced HER2 positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 36, pp. e16069 - e16069, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e16069

Doherty M; Tam VC; McNamara MG; Hedley DW; Dhani NC; Chen EX; Jang RW-J; Tang PA; Sim H-W; O'Kane GM; DeLuca S; Wang L; Brooks K; Knox JJ, 2018, 'Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.4084

Natori A; Sim H-W; Chan BA; Sun P; Moignard S; Yokom D; Lim CH; Jiang M; Ma LX; Chen EX; Liu G; Knox JJ; Darling GE; Yeung JC-W; Wong R; Hafezi-Bakhtiari S; Conner J; Rogalla P; Jang RW-J; Elimova E, 2018, 'Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 36, pp. 122 - 122, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.122

Yokom D; Natori A; Sim H-W; Chan BA; Moignard S; Sun P; Lim CH; Jiang DM; Ma LX; Darling GE; Swallow CJ; Brierley JD; Wong R; Liu G; Chen EX; Knox JJ; Alibhai SMH; Jang RW-J; Elimova E, 2018, 'Management of metastatic gastric and esophageal cancer in older adults.', Journal of Clinical Oncology, 36, pp. 163 - 163, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.163

Lim CH; Yokom D; Jiang DM; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Moignard S; Knox JJ; Chen EX; Liu G; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Outcomes for advanced HER2-positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 36, pp. 131 - 131, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.131

Jiang DM; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Knox JJ; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Jang RW-J; Elimova E, 2018, 'Patterns of recurrence and outcomes after curative resection of locally advanced HER2-positive gastroesophageal cancer (HPGEC).', Journal of Clinical Oncology, 36, pp. 147 - 147, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.147

Ma LX; Lim CH; Sun P; Jiang M; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Le LW; Chen EX; Liu G; Swallow CJ; Darling GE; Kongkham PN; Shultz D; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Relationship between human epidermal growth factor receptor 2 (HER2) status and central nervous system metastases in gastroesophageal cancer.', Journal of Clinical Oncology, 36, pp. 145 - 145, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.145

Chan BA; Sim H-W; Natori A; Moignard S; Yokom D; Lim CH; Jiang DM; Chen EX; Knox JJ; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Hafezi-Bakhtiari S; Elimova E; Jang RW-J, 2018, 'Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ) adenocarcinoma.', Journal of Clinical Oncology, 36, pp. 148 - 148, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.148

O'Kane GM; Fraser A; Moignard S; Dodd A; Creighton S; Sim H-W; Aung KL; Borgida A; Gallinger S; Knox JJ, 2018, 'The impact of lung and bone metastases on prognosis in advanced PDAC.', Journal of Clinical Oncology, 36, pp. 494 - 494, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.494

Sim HW; Morgan ER; Mason WP, 2018, 'Contemporary management of high-grade gliomas', CNS Oncology, 7, pp. 51 - 65, http://dx.doi.org/10.2217/cns-2017-0026

Stukalin I; Connor Wells J; Fraccon A; Pasini F; Porta C; Lalani AKA; Srinivas S; Alex Bowman I; Brugarolas J; Lee JL; Donskov F; Beuselinck B; Bamias A; Rini BI; Sim HW; Agarwal N; Rha SY; Kanesvaran R; Choueiri TK; Heng DYC, 2018, 'Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)', Kidney Cancer, 2, pp. 31 - 36, http://dx.doi.org/10.3233/KCA-170020

Sim HW; Knox J, 2018, 'Hepatocellular carcinoma in the era of immunotherapy', Current Problems in Cancer, 42, pp. 40 - 48, http://dx.doi.org/10.1016/j.currproblcancer.2017.10.007

Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA, 2018, 'Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma', International Journal of Cancer, 142, pp. 57 - 65, http://dx.doi.org/10.1002/ijc.31039

Sim HW; Knox J; Dawson LA, 2017, 'An Update on Randomized Clinical Trials in Hepatocellular Carcinoma', Surgical Oncology Clinics of North America, 26, pp. 647 - 666, http://dx.doi.org/10.1016/j.soc.2017.05.006

Jiang DM; Sim H-W; Siu LL; Shapiro JD; Liu G; Price TJ; Jonker DJ; Karapetis CS; Strickland A; Zhang W; Jeffery M; Tu D; Ng S; Sabesan SS; Shannon J; Townsend AR; Morgen E; Xu W; O'Callaghan CJ; Chen EX, 2017, 'Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).', Journal of Clinical Oncology, 35, pp. 3600 - 3600, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3600

Yip S; Wells C; Moreira RB; Wong A; Srinivas S; Beuselinck B; Porta C; Sim H-W; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood L; Canil CM; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2017, 'Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).', Journal of Clinical Oncology, 35, pp. 4580 - 4580, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4580

Bosse D; Xie W; Wells C; Lalani A-KA; Donskov F; Bent A; Sim H-W; Beuselinck B; Bamias A; Porta C; Vaishampayan UN; Pal SK; Agarwal N; Srinivas S; Rini BI; Alva AS; Wood L; Kapoor A; Choueiri TK; Heng DYC, 2017, 'Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).', Journal of Clinical Oncology, 35, pp. e16065 - e16065, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16065

Sim H-W; Nejad R; Zhang W; Mason WP; Bernstein M; Aldape K; Zadeh G; Chen EX, 2017, 'Comparison of 2-hydroxyglutarate (2HG) levels in tissue and serum of isocitrate dehydrogenase (IDH)-mutated (MUT) versus wild-type (WT) gliomas.', Journal of Clinical Oncology, 35, pp. 2037 - 2037, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2037

Sim H-W; Chan BA; Natori A; Lim CH; Jiang DM; Moignard S; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW-J; Elimova E, 2017, 'Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer.', Journal of Clinical Oncology, 35, pp. 4053 - 4053, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4053

Samawi H; Sim H-W; Chan KK; Alghamdi MA; Lee-Ying RM; Knox JJ; Gill P; Romagnino A; Batuyong E; Ko Y-J; Cheung WY; Tam VC, 2017, 'Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database.', Journal of Clinical Oncology, 35, pp. e15653 - e15653, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15653

Alghamdi MA; Lee-Ying R; Sim H-W; Samawi H; Knox JJ; Romagnino A; Ko Y-J; Chan KK; Swiha M; Batuyong E; Cheung WY; Tam VC, 2017, 'Effect of sorafenib (S) starting dose and dose intensity on survival in patients with hepatocellular carcinoma (HCC): Results from a Canadian multicenter HCC database.', Journal of Clinical Oncology, 35, pp. 4084 - 4084, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4084

Basappa NS; Lalani A-KA; Kalirai A; Li H; Wood L; Kollmannsberger CK; Sim H-W; Kapoor A; Hotte SJ; Czaykowski P; Canil CM; Reaume MN; Bjarnason GA; Vanhuyse M; Soulieres D; North SA; Heng DYC, 2017, 'Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).', Journal of Clinical Oncology, 35, pp. e16078 - e16078, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16078

Natori A; Chan BA; Sim H-W; Ma LX; Yokom D; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Elimova E; Jang RW-J, 2017, 'Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 35, pp. 10037 - 10037, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.10037

Stukalin I; Wells C; Fraccon AP; Pasini F; Porta C; Moreira RB; Srinivas S; Bowman IA; Brugarolas J; Lee J-L; Donskov F; Beuselinck B; Bamias A; Rini BI; Sim H-W; Agarwal N; Rha SY; Kanesvaran R; Choueiri TK; Heng DYC, 2017, 'Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).', Journal of Clinical Oncology, 35, pp. 498 - 498, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.498

Basappa NS; Lalani A-KA; Li H; Kalirai A; Wood L; Kollmannsberger CK; Sim H-W; Kapoor A; Hotte SJ; Czaykowski P; Canil CM; Reaume MN; Bjarnason GA; Vanhuyse M; Soulieres D; Levesque E; North SA; Heng DYC, 2017, 'Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).', Journal of Clinical Oncology, 35, pp. 468 - 468, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.468

Yip S; Wells C; Moreira RB; Wong A; Srinivas S; Beuselinck B; Porta C; Sim H-W; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood L; Soulieres D; Canil CM; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2017, 'Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.', Journal of Clinical Oncology, 35, pp. 492 - 492, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.492

Jiang DM; Sim H-W; Siu LL; Shapiro JD; Liu G; Price TJ; Jonker DJ; Karapetis CS; Strickland A; Zhang W; Jeffery M; Tu D; Ng S; Sabesan SS; Shannon J; Townsend AR; Morgen E; Xu W; O'Callaghan CJ; Chen EX, 2017, 'Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).', Journal of Clinical Oncology, 35, pp. 699 - 699, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.699

Sim H-W; Chan B; Natori A; Lim CH; Jiang DM; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Jang RW-J; Elimova E, 2017, 'Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 35, pp. 126 - 126, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.126

Natori A; Chan B; Sim H-W; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J-HJ; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Elimova E; Jang RW-J, 2017, 'Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 35, pp. 189 - 189, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.189

Lalani AKA; Li H; Heng DYC; Wood L; Kalirai A; Bjarnason GA; Sim HW; Kollmannsberger CK; Kapoor A; Hotte SJ; Vanhuyse M; Czaykowski P; Reaume MN; Soulieres D; Venner P; North S; Basappa NS, 2017, 'First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience', Journal of the Canadian Urological Association, 11, pp. 112 - 117, http://dx.doi.org/10.5489/cuaj.4398

Yip SM; Ruiz Morales JM; Donskov F; Fraccon A; Basso U; Rini BI; Lee JL; Bjarnason GA; Sim HW; Beuselinck B; Kanesvaran R; Brugarolas J; Koutsoukos K; Fu SYF; Yuasa T; Davis I; Alva A; Kollmannsberger C; Choueiri TK; Heng DYC, 2017, 'Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)', Kidney Cancer, 1, pp. 41 - 47, http://dx.doi.org/10.3233/KCA-160002

Nejad R; Sim H; Aldape K; Mason W; Bernstein M; Gentili F; Kalia S; Tung T; Chen E; Zadeh G, 2017, 'P10.21 2-hydroxyglutarate as a biomarker for IDH mutation in low grade gliomas', Neuro-Oncology, 19, pp. iii89 - iii90, http://dx.doi.org/10.1093/neuonc/nox036.339

Back to profile page